Role of Oxidative Stress and ROS in Multiple Sclerosis: New Treatments
Reactive oxygen species (ROS) play a crucial role in the pathogenesis of multiple sclerosis (MS) by mediating demyelination and axonal damage, which are key pathological features of the disease. ROS, which include free radicals and other oxygen-derived molecules, act as critical signaling molecules in normal physiological functions. However, when produced excessively, ROS can lead to oxidative stress, resulting in damage to cellular components such as proteins, lipids, and DNA. In the context of MS, the overproduction of ROS has been linked to the destruction of myelin sheaths and axons, contributing to the progression of the disease.
Current treatments for multiple sclerosis that target reactive oxygen species (ROS) include exploring ROS as a potential drug target for myelin repair, as investigated in a project funded by the MS Society at the University of Cambridge. Additionally, antioxidant protection is considered a potential therapeutic target for MS, aiming to counteract the role of ROS in both the initial and chronic stages of the disease. Moreover, cell-based therapies like mesenchymal stem cells (MSCs) have shown promise in restoring homeostasis in MS by modulating ROS levels and promoting neuroprotection and repair. These approaches highlight the evolving strategies in MS treatment that focus on addressing the impact of ROS on disease progression.
Oxidative Stress and Inflammation
The interplay between oxidative stress and inflammation in multiple sclerosis (MS) is a critical factor in disease progression. In MS, inflammation, a key characteristic, is exacerbated by oxidative stress. Reactive oxygen species (ROS) play a role in modulating cell signaling proteins, affecting inflammatory pathways, and contributing to the chronic inflammatory state seen in MS patients. The overactivation of inflammatory responses, often initiated by factors like infection or tissue damage, can result in tissue destruction and the neurological deficits typical of MS.
Some symptoms of oxidative stress in multiple sclerosis (MS) patients include spasticity, chronic pain, fatigue, motor and mobility disorders, and cognitive impairment. Additionally, studies have shown increased concentrations of reactive oxygen species in the cerebrospinal fluid of MS patients, as well as dysregulated levels of malondialdehyde (MDA), superoxide dismutase (SOD), and glutathione (GSH) in the blood of MS patients. However, there have been inconsistent findings regarding oxidative stress marker levels in MS patients, highlighting the complexity of oxidative stress in the context of MS.
Some current treatments for oxidative stress in multiple sclerosis (MS) patients include the use of medications like natalizumab and fingolimod, which have been shown to have a positive effect on antioxidant capacity and may reduce oxidative stress markers. Additionally, dimethyl fumarate (DMF) is known for its role in modulating oxidative stress molecules and reducing oxidative damage in MS patients. Mitoxantrone, on the other hand, may increase oxidative stress, but combining it with antioxidant supplementation like N-acetylcysteine has been suggested. Antioxidants are being explored as a potential therapeutic approach to counteract oxidative stress in MS, with the aim of improving outcomes for patients. Further research is needed to evaluate the effectiveness of new antioxidants in managing oxidative stress in MS patients.
The mechanism of action of natalizumab in reducing oxidative stress in multiple sclerosis (MS) patients involves not only its role in reducing the inflammatory process but also its direct effect on decreasing oxidative damage. Natalizumab has been shown to have beneficial effects related to the reduction of oxidative damage biomarkers in MS patients. By targeting both inflammation and oxidative stress, natalizumab plays a dual role in mitigating the pathological processes associated with MS, ultimately contributing to improved outcomes for patients.
Reference:
Ohl, K., Tenbrock, K., & Kipp, M. (2016). Oxidative stress in multiple sclerosis: Central and peripheral mode of action. Experimental neurology, 277, 58-67.
Ramos-González, E. J., Bitzer-Quintero, O. K., Ortiz, G., Hernández-Cruz, J. J., & Ramírez-Jirano, L. J. (2021). Relationship between inflammation and oxidative stress and its effect on multiple sclerosis. Neurologia.
Zhang, S. Y., & Cheng, Y. (2020). Oxidative stress marker aberrations in multiple sclerosis: A meta-analysis study. Frontiers in neuroscience, 14, 526067.
Adamczyk, B., & Adamczyk-Sowa, M. (2016). New insights into the role of oxidative stress mechanisms in the pathophysiology and treatment of multiple sclerosis. Oxidative medicine and cellular longevity, 2016.
Zarzuelo Romero, M. J., Pérez Ramírez, C., Carrasco Campos, M. I., Sánchez Martín, A., Calleja Hernández, M. Á., Ramírez Tortosa, M. C., & Jiménez Morales, A. (2021). Therapeutic value of single nucleotide polymorphisms on the efficacy of new therapies in patients with multiple sclerosis. Journal of Personalized Medicine, 11(5), 335.
